Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$19.0M
26M shares
52-week range
$0.51 – $1.45
24% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
5.81%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $2.5M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $3.4M | $2.5M | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — |
| R&D | $4.8M | $7.3M | $25.7M | $34.8M | $33.0M | $14.2M | $4.1M |
| Operating income | −$54.0M | −$16.4M | −$65.8M | −$48.4M | −$348.1M | $73.0M | −$12.8M |
| EBITDA | −$47.5M | −$15.5M | −$36.9M | −$52.5M | −$52.7M | −$27.7M | −$16.2M |
| Net income | $172.9M | −$32.9M | −$55.6M | −$52.6M | −$384.6M | $42.0M | −$39.2M |
| Net margin | 5151.0% | -1307.1% | — | — | — | — | — |
| EPS (diluted) | 1481.04 | -547.60 | -31.73 | -27.25 | -4.99 | 72.93 | -3.95 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-1.05 | $-1.05–$-1.05 | 1 |
| 2027 | $2M | $-30.24 | $-30.24–$-30.24 | 1 |
| 2028 | $88M | $16.56 | $16.56–$16.56 | 1 |
Forward consensus · source: Financial Modeling Prep
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
www.aeonbiopharma.comNo one on the platform currently holds AEON.
No tracked institution reports a position in AEON as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-02-26 | 1-for-72reverse |
No one on the platform has traded AEON yet.
| $28M |
| — |
| CLNNClene Inc. | $6.06 | +4.66% | $62M | — |
| CLRBCellectar Biosciences, Inc. | $2.52 | +2.02% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
$AEON got a starter first of up to 3 buys spread out over a few days to a few weeks ideally looking for a pop to .9+ would add again around low .6s if it gets there ❄️
View on StockTwits ↗$AEON I'm jumping ship. Far too long believing in this company. I survived their last reverse split only to re-accumulate another losing hand. Thousands in losses and a current average this stock will perhaps never see... It's time. Good luck to all, hope this pans out for future investors.
View on StockTwits ↗$AEON all you folks still holding out for hope? Or has anyone else pulled out?
View on StockTwits ↗$AEON $PSTV as the reat if Pharma: it is near impossible to get drugs through the current FDA. A few other bio stocks I follow have the same issue. Slow-rolling and then the requirement to negotiate for more and more working capital. Then these companies are making deals to insiders friends, basically paying out shares as protection to defend against coordinated short attacks. The shorts understand that R. Kennedy has no intention of helping, he is profiting off this. The industry is garbage right now.
View on StockTwits ↗$AEON No price bounce after Headache Society presentation in Orlando. Stagnant.
View on StockTwits ↗$AEON My theory on why this hasn’t moved yet and this is ALL SPECULATION, is that the PDT rule gets lifted in a few days. There haven’t really been many hard pumps yet and I think part of that could be because everyone is waiting for this rule to officially go away.
View on StockTwits ↗$AEON I'm thinking August is coming..fast. Can I assume that if they can't get back to 1.00usd, and maintain it, they may request another reverse split? Seems even now it would be a rushed vote to clear way for such action. I went through the last reverse with these guys...it's ugly, especially when their price continues to fall or lay stagnant post split.
View on StockTwits ↗$AEON read the filings. they have no clue when they will be ready.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.